Somatostatin: Linking Cognition and Alzheimer Disease to Therapeutic Targeting,Pharmacological Reviews

当前位置： X-MOL 学术 › Pharmacol. Rev. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Somatostatin: Linking Cognition and Alzheimer Disease to Therapeutic Targeting
Pharmacological Reviews ( IF 19.3 ) Pub Date : 2024-11-01 , DOI: 10.1124/pharmrev.124.001117
Karin E Sandoval ₁ , Ken A Witt ₂

Affiliation

Over 4 decades of research support the link between Alzheimer disease (AD) and somatostatin [somatotropin-releasing inhibitory factor (SRIF)]. SRIF and SRIF-expressing neurons play an essential role in brain function, modulating hippocampal activity and memory formation. Loss of SRIF and SRIF-expressing neurons in the brain rests at the center of a series of interdependent pathological events driven by amyloid-β peptide (Aβ), culminating in cognitive decline and dementia. The connection between the SRIF and AD further extends to the neuropsychiatric symptoms, seizure activity, and inflammation, whereas preclinical AD investigations show SRIF or SRIF receptor agonist administration capable of enhancing cognition. SRIF receptor subtype-4 activation in particular presents unique attributes, with the potential to mitigate learning and memory decline, reduce comorbid symptoms, and enhance enzymatic degradation of Aβ in the brain. Here, we review the links between SRIF and AD along with the therapeutic implications.

中文翻译：

生长抑素：将认知和阿尔茨海默病与治疗靶向联系起来

超过 4 年的研究支持阿尔茨海默病（AD）与生长抑素 [生长激素释放抑制因子（SRIF）] 之间的联系。SRIF 和表达 SRIF 的神经元在大脑功能中起着重要作用，调节海马活动和记忆形成。大脑中 SRIF 和表达 SRIF 的神经元的缺失是一系列由β淀粉样蛋白肽（A β）驱动的相互依赖的病理事件的中心，最终导致认知能力下降和痴呆。SRIF 和 AD 之间的联系进一步延伸到神经精神症状、癫痫发作活动和炎症，而临床前 AD 调查显示 SRIF 或 SRIF 受体激动剂给药能够增强认知。SRIF 受体亚型 4 激活尤其具有独特的属性，有可能减轻学习和记忆能力下降，减少合并症症状，并增强大脑中 Aβ的酶降解。在这里，我们回顾了 SRIF 和 AD 之间的联系以及治疗意义。

更新日期：2024-10-16

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南